Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,600 shares of the firm’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $170.81, for a total transaction of $273,296.00. Following the transaction, the chief executive officer now directly owns 284,115 shares in the company, valued at $48,529,683.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Bruce C. Cozadd also recently made the following trade(s):
- On Friday, June 1st, Bruce C. Cozadd sold 7,000 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $168.86, for a total transaction of $1,182,020.00.
Shares of JAZZ traded up $3.55 during mid-day trading on Thursday, reaching $176.49. The company had a trading volume of 492,600 shares, compared to its average volume of 506,840. Jazz Pharmaceuticals PLC has a 1-year low of $128.58 and a 1-year high of $184.00. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The company has a market cap of $10.43 billion, a P/E ratio of 18.35, a PEG ratio of 0.95 and a beta of 0.96.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $2.98 earnings per share for the quarter, beating analysts’ consensus estimates of $2.78 by $0.20. Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The company had revenue of $444.61 million for the quarter, compared to the consensus estimate of $435.69 million. During the same period last year, the company posted $2.31 EPS. The firm’s quarterly revenue was up 18.2% compared to the same quarter last year. equities analysts forecast that Jazz Pharmaceuticals PLC will post 11.63 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in shares of Jazz Pharmaceuticals by 2.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,244,800 shares of the specialty pharmaceutical company’s stock valued at $167,612,000 after purchasing an additional 28,700 shares in the last quarter. FIL Ltd boosted its stake in shares of Jazz Pharmaceuticals by 1.0% in the 1st quarter. FIL Ltd now owns 908,737 shares of the specialty pharmaceutical company’s stock valued at $137,211,000 after purchasing an additional 8,935 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 29.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 755,623 shares of the specialty pharmaceutical company’s stock valued at $101,745,000 after purchasing an additional 171,174 shares in the last quarter. Compagnie Lombard Odier SCmA acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $577,000. Finally, Teachers Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 16.1% in the 4th quarter. Teachers Advisors LLC now owns 601,785 shares of the specialty pharmaceutical company’s stock valued at $81,030,000 after purchasing an additional 83,426 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.
A number of equities analysts recently commented on JAZZ shares. BidaskClub raised shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Wells Fargo & Co set a $182.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, May 15th. BMO Capital Markets raised their price target on shares of Jazz Pharmaceuticals from $199.00 to $201.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 9th. ValuEngine raised shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. Finally, Royal Bank of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, June 1st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $183.70.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.